Status:
COMPLETED
Valnoctamide in Mania
Lead Sponsor:
Beersheva Mental Health Center
Collaborating Sponsors:
Stanley Medical Research Institute
Conditions:
Mania
Schizoaffective Disorder, Manic Type
Eligibility:
All Genders
18-60 years
Phase:
PHASE3
Brief Summary
Valproic acid is a leading mood stabilizer for the treatment of bipolar disorder. Its well-known teratogenicity limits its use in young women of childbearing age. According to toxicologic studies the ...
Detailed Description
Valproic acid is a leading mood stabilizer for the treatment of bipolar disorder. Its well-known teratogenicity limits its use in young women of childbearing age (1-3). The alternative mood stabilizer...
Eligibility Criteria
Inclusion
- Ages 18-60
- Males or females
- DSM-IV criteria for mania or schizoaffective disorder, manic type
- Minimal Young Mania Scale = 20
- Admittance to hospital within previous 72 hours
Exclusion
- Any active physical illness
- Pregnancy
- Drug or alcohol abuse
- Suicidal or violent ideation
Key Trial Info
Start Date :
September 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
May 1 2008
Estimated Enrollment :
80 Patients enrolled
Trial Details
Trial ID
NCT00140179
Start Date
September 1 2004
End Date
May 1 2008
Last Update
November 25 2009
Active Locations (3)
Enter a location and click search to find clinical trials sorted by distance.
1
Hemek Medical Center
Afula, Israel
2
Barzilai Medical Center
Ashkelon, Israel
3
Beersheva Mental Health Center
Beersheva, Israel